Disease Information

General Information of the Disease (ID: DIS00340)

• Name: Prostate hyperplasia
• ICD: ICD-11: GA90

Type(s) of Resistant Mechanism of This Disease

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Everolimus

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: NPR2 like, GATOR1 complex subunit (NPRL2) [1]

• Resistant Disease: Prostate hyperplasia [ICD-11: GA90.0]
• Molecule Alteration: Expression; Up-regulation
• Resistant Drug: Everolimus
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: mTOR signaling pathway; Inhibition; hsa04150
• In Vitro Model: PC3 cells; Prostate; Homo sapiens (Human); CVCL_0035
• In Vitro Model: RWPE-1 cells; Prostate; Homo sapiens (Human); CVCL_3791
• In Vitro Model: PCa LNCaP cells; Prostate; Homo sapiens (Human); CVCL_D575
• In Vivo Model: Balb/c athymic nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Western blotting assay
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.NPRL2-silencing increased the activity of mTOR signaling, and the autophagy attenuation induced by NPRL2-silencing in EVS-treated CRPC cells was associated with the increase of apoptosis.

References

• Ref 1: NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer .Prostate. 2019 Jan;79(1):44-53. doi: 10.1002/pros.23709. Epub 2018 Sep 3. 10.1002/pros.23709